International Journal of Proteomics

International Journal of Proteomics / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 1384523 | 19 pages |

S-Nitrosylation Proteome Profile of Peripheral Blood Mononuclear Cells in Human Heart Failure

Academic Editor: Christoph H. Borchers
Received30 Jan 2016
Revised07 Apr 2016
Accepted16 May 2016
Published18 Aug 2016


Nitric oxide (NO) protects the heart against ischemic injury; however, NO- and superoxide-dependent S-nitrosylation (S-NO) of cysteines can affect function of target proteins and play a role in disease outcome. We employed 2D-GE with thiol-labeling FL-maleimide dye and MALDI-TOF MS/MS to capture the quantitative changes in abundance and S-NO proteome of HF patients (versus healthy controls, /group). We identified 93 differentially abundant (59-increased/34-decreased) and 111 S-NO-modified (63-increased/48-decreased) protein spots, respectively, in HF subjects (versus controls, fold-change ≥1.5, ). Ingenuity pathway analysis of proteome datasets suggested that the pathways involved in phagocytes’ migration, free radical production, and cell death were activated and fatty acid metabolism was decreased in HF subjects. Multivariate adaptive regression splines modeling of datasets identified a panel of proteins that will provide >90% prediction success in classifying HF subjects. Proteomic profiling identified ATP-synthase, thrombospondin-1 (THBS1), and vinculin (VCL) as top differentially abundant and S-NO-modified proteins, and these proteins were verified by Western blotting and ELISA in different set of HF subjects. We conclude that differential abundance and S-NO modification of proteins serve as a mechanism in regulating cell viability and free radical production, and THBS1 and VCL evaluation will potentially be useful in the prediction of heart failure.

1. Introduction

Of the 57 million global deaths annually, 17.3 million (~30%) are due to cardiovascular diseases [1, 2]. Heart failure (HF) is a clinical syndrome that manifests as a consequence of the diverse factors including myocardial infarction, hypertension, cardiomyopathies, and atrial fibrillation. The intimate relationship of the micro- and macroenvironment with the cardiomyocytes results in cellular events that may be important to the initiation and propagation of HF, though a clear understanding of the molecular mechanisms underlying HF is not available. Some studies have identified HF-associated alterations in Ca2+ handling, energy metabolism, and contractile function in experimental models (reviewed in [3]); however, how these processes promote HF pathophysiology and if these processes are relevant to human HF remain unclear.

Nitric oxide (NO) protects the heart against ischemic injury, and NO-based therapy is part of the standard of care in patients with heart failure [4]. The classic view holds that NO acts primarily as a vasodilator; however, it is not known how NO protects the ischemic heart. There has been growing appreciation that endogenous nitrosylating compounds called S-nitrosothiols are involved in ischemic cardioprotection [5]. An alternative view is that NO present in conjunction with ROS results in the formation of peroxynitrite (H2O2 + → ONOO + H2O) that is highly stable and soluble and can induce S-nitrosylation (S-NO) of cysteine residues on target proteins [6], potentially altering their function. Thus, protein S-NO modification may ameliorate cardiac injury or cause protein dysfunction.

Currently there are a limited number of clinically approved biomarkers available for the management of the entire spectrum of cardiovascular diseases [7]. These markers include serum cholesterol total/LDL, creatine kinase myocardial isoform (CK-MB), cardiac troponins (cTnI and cTnT), and brain natriuretic peptide (BNP) or its precursor N-terminus isoform (NT-proBNP). Of these only BNP/NT-proBNP has been validated for heart failure patients [8]. These biomarkers, though useful, provide a limited view of the disease status, and there is a need for the identification of new biomarkers of HF.

Peripheral blood mononuclear cells (i.e., PBMCs) carry the inherent genetic signature of the host and serve as an accessible and useful tissue capable of detecting and responding to stimuli, similar to what may be induced in the body [912]. Recent studies have distinguished the gene expression profile in peripheral blood leukocytes of stroke patients [13, 14]. Yet, proteomics, which incorporates the comprehensive characterization of all facets of protein biology, including the determination of protein localization, modifications, interactions, activities, and ultimately their function, is particularly well suited for advancing our understanding of complex disease mechanisms like HF. Importantly, the proteome is highly dynamic owing to a large range of protein expression and presence of a myriad of protein forms or “proteoforms” [15] that may arise from mutations, truncations, alternative splicing events, and the addition of posttranslational modifications (PTMs).

In this study, we aimed to identify the networks of proteins that are disturbed in abundance or posttranslational S-NO modifications and determine the evolution of chronic HF in human patients. Peripheral blood cells are shown to produce nitric oxide in various clinical situations, and a significant increase in the expression and activity of inducible nitric oxide synthase is noted in PBMCs of chronic heart failure patients [16]. We utilized saturation thiol-labeling maleimide dye that exhibits stable, specific, quantitative labeling of cysteine residues in conjunction with 2D-GE approach and mass spectrometry [1719] for developing the PBMCs proteome of the normal healthy (NH) and HF subjects ( = 30/group). Importantly, our approach included steps that allowed simultaneous discovery of protein abundance and S-NO modifications for evaluating the PBMC’s proteome [2022]. This approach combines the resolving power of two-dimension gel electrophoresis (2D-GE) [23, 24] with the highly quantitative nature of saturation fluorescence [25] to permit S-NO and abundance change quantification with minimal processing steps that lead to major losses experienced by other S-NO technology (e.g., biotin-switch technique). Proteome datasets were submitted to modeling analysis for (a) identifying the potential pathways that were disturbed and (b) top molecules that were altered in abundance or S-NO levels in HF subjects. We have employed traditional ELISA, Western blotting, and biotin-switch assay for targeted analysis of a new batch of PBMC samples ( = 15/group) and verified the differential abundance and S-NO levels of THBS1 polypeptide and VCL in HF (versusNH) subjects. We discuss the molecular mechanisms that might be disturbed in progression of HF.

2. Materials and Methods

2.1. Ethics Statement for the Use of Human Samples

All procedures were approved by the Institutional Review Boards at the UTMB, Galveston. Samples were decoded and deidentified before they were utilized for research purposes. Blood samples (10 mL) were collected with K3EDTA (1.5-mg/mL blood). Subjects with a degree of systolic dysfunction (ejection fraction: ≤54%), left ventricular dilatation (end diastolic diameter ≥57 mm), and blood levels of NT-proBNP >1000 ng/L that reflects NYHA classification II-III of cardiac involvement were identified as those at risk of heart failure. Subjects with no signs of systolic dysfunction (ejection fraction: ≥55) or ventricular dilation and blood levels of NT-proBNP <400 ng/L were included as healthy controls. For the proteomic studies, blood samples were obtained from HF subjects (, 56% males, age range: 58–71 years, average: 62 years) and NH controls (, 60% males, age range: 28–65 years, average: 59.5 years).

2.2. PBMC Isolation, BODIPY Labeling, and 2D-GE

All chemicals and reagents were of molecular grade (>99.5% purity). Heparinized Vacutainer CPT Cell Preparation Tubes (Becton Dickinson, Franklin Lakes, NJ) containing <8 mL of whole blood samples were centrifuged following manufacturer’s instruction. The PBMCs were harvested using a FICOLL Hypaque density gradient (GE Healthcare, Piscataway, NJ) and centrifuged again at 300 ×g for 10 min at room temperature to pellet the cells. The cell pellets consisting of 8–10-million PBMCs were washed with RPMI-1640 medium and stored at −80°C until analysis.

PBMC pellets from individual study subjects were lysed in 7 M urea, 2 M thiourea, 2% CHAPS, and 50 mM Tris (pH 7.5), containing benzonase nuclease (300-units/mL) [24]. Protein concentrations were determined with the Lowry method and cysteines (cysteic acid) determined by amino acid analysis (Model L8800, Hitachi High Technologies America, Pleasanton, CA) [18, 20]. Samples thus analyzed yielded ~200 pmol of Cys/μg of protein. At least 92% of all human proteins contain at least one cysteine residue [26] and thus can be detected using the thiol-labeling maleimide dye [18, 20]. To detect the changes in abundance and S-NO modification levels, each sample was split into two fractions (each fraction containing 100 μg of protein) [27]. Because some cysteine thiols are hyperreactive that can be oxidized under aerobic conditions in few minutes if without any protection [28], we immediately treated one fraction with copper chelator neocuproine (100 µM for 1 h) that is shown to prevent S-NO reduction and stabilize S-NO during further processing of samples. The second protein fraction was incubated for 1 h with 6 mM ascorbate to ensure all cysteine residues were reduced and available for dye-binding. Both fractions were dialyzed against the urea buffer in the cold to remove ascorbate or to serve as a process control and then labeled with BODIPY® FL N-(2-aminoethyl) maleimide (BD from Life Technologies, Grand Island, NY) at 60-fold excess to cysteine that ensured sufficient dye was available to label all available cysteine residues [20], thereby ensuring reproducibility and accuracy. The mixtures were incubated for 2 h; then the reactions were stopped with a 10-fold molar excess of 2-mercaptoethanol (2-ME) over dye. All incubations were carried out at room temperature in the dark in 200 μL reaction volume. As we utilized 100 µg protein sample labeled with 60-fold molar excess dye over thiol all within a volume of 200 µL, we used 6 µmol/mL of BD per sample, and 60 µmol/mL of 2-ME.

All BD-labeled, Asc+ and Asc PBMC lysates (100 µg protein) were separated by 2-dimensional gel electrophoresis (2D-GE), employing an IPGphor multiple sample isoelectric focusing (IEF) device (GE Healthcare) in the first dimension and the Criterion Dodeca cell (Bio-Rad, Hercules, CA) in the second dimension [29, 30]. Sample aliquots were first loaded onto 11 cm dehydrated precast immobilized pH gradient (IPG) strips (pH range 3–11, from GE Healthcare) and rehydrated overnight. IEF was performed at 20°C with the following parameters: 50 V, 11 hours; 250 V, 1 hour; 500 V, 1 hour; 1,000 V, 1 hour; 8,000 V, 2 hours; 8,000 V, 48,000 V/hr. The IPG strips were then incubated in 10 mL of equilibration buffer (6 M urea, 2% sodium dodecyl sulfate (SDS), and 50 mM Tris-HCl, pH 8.8, 20% glycerol) for 30 minutes at 22°C with shaking [29, 30]. Electrophoresis was performed at 150 V for 2.25 hours, 4°C with precast 8–16% polyacrylamide gels in Tris-glycine-SDS buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% SDS, pH 8.3) [29, 30].

2.3. Image Processing and Analysis

In total, 120 BODIPY-stained 2D-GE gels (2 gels with either Asc+ or Asc protein lysates per sample for the HF () and NH () subjects) were run by us. After electrophoresis, gels were fixed in 20% methanol, 7% acetic acid, and 10% acetonitrile for 1 h and washed with 20% ethanol and 10% acetonitrile to reduce background. The gels were imaged at 100 µm resolution using the Typhoon Trio Variable Mode Imager (GE Healthcare) to quantify BD-labeled proteins ().

All gels were analyzed using the SameSpots software. The current version of Totallab Ltd. SameSpots software (formerly Nonlinear Dynamics, Ltd., Newcastle, UK), unlike traditional analysis, does not rely on propagating and matching spots to an arbitrary reference. Instead, it relies on geometric correction of the scans themselves and projecting them all into the same reference space, performing pixel-to-pixel matching before spot detection. This approach ensures that spot boundaries are the same for all gels, eliminating errors that accumulate in the reference gel(s) as the number of gels within one experiment increases. The software selects one reference gel according to several criteria including quality and number of spots with the intent on selecting the gel that best represents all the gels. The reference gel containing the most common features was selected from the pool of gels. To ensure that maximum number of proteins were detected, the reference gel was stained with SyproRuby (from Life Technologies, Grand Island, NY) and scanned at to ensure that all proteins (irrespective of presence or absence of cysteine residue) were detected. The exposure time for both dyes was adjusted to achieve a value of ~55,000–63,000 pixel intensity (16-bit saturation) from the most intense protein spots on the gel [29, 30].

For identifying the differential proteome, all the 2D gel images were assessed for quality control by SameSpots software and then aligned both manually and automatically against the reference gel. After manual and automated pixel-to-pixel alignment, spot boundaries were detected and the fluorescence intensity of each protein spot was normalized by using a bias factor calculated assuming most spots did not change across the experiment. The SyproRuby stained reference gel was used to define spot boundaries; however, the gel images taken under the BD-specific filters were used to obtain the quantitative spot data. This strategy ensured that spot numbers and outlines were identical across all gels in the experiment, eliminating problems with unmatched spots [30] as well as ensuring that the greatest number of protein spots and their spot volumes were accurately detected and quantified.

The detailed protocol for quantification of protein abundance and cysteinyl-S-nitrosylation by BD labeling is recently described by us [20]. Briefly, protein spot abundance ratios were calculated from normalized spot volumes from Asc+ HF sample versus the matched normal spot volumes (protein abundance = Asc+ HF/Asc+ NH). Spot volumes were normalized for each sample using a software-calculated bias value assuming that the great majority of spot volumes did not change in abundance (log (abundance ratio) = 0). The scatter of the log (abundance ratios) for each spot in a gel (sample) is distributed around a mean value that represents the systematic factors that govern the experimental variation. Thus, a gain factor is calculated to adjust the mean spot ratios of a given gel to 0 (log (abundance ratio) = 0) and applied to each spot volume [23]. The S-NO modification levels were quantified by calculation of the ratio of fluorescence units from Asc aliquots (S-NO = Asc HF/Asc NH). Finally, the ratio of ratios, that is, S-NO/protein abundance = [Asc HF/Asc NH]/[Asc+ HF/Asc+ NH], was calculated to obtain the change in S-NO levels normalized for protein abundance [20, 21]. As S-NO modification inhibits the Cys-BODIPY fluorescence; a negative RoR value would indicate an increase in S-NO level (and vice versa) in the sample.

For the purpose of selecting differentially abundant and S-NO-modified protein spots for mass spectrometry, normalized spot volumes were subjected to statistical analysis using in-built tools in Totallab SameSpots software. Spot volumes were log2 transformed and spot-wise standard deviation, arithmetic mean, and coefficient of variation (CoV) values of the standard abundance (and S-NO) were calculated for each spot [31]. Student’s t-test with Welch’s correction for unequal variances was used to test for differential protein abundance and S-NO level between NH controls and HF subjects. Benjamini-Hochberg multiple hypothesis testing correction was applied to account for the false discovery rate and significance was accepted at . The protein spots identified to be differentially abundant or differentially S-NO modified (fold change |≥1.5|, ) in HF subjects were submitted for mass spectrometry identification.

2.4. Mass Spectrometry and Protein Identification

Selected 2D-GE spots that exhibited significant differential prevalence in HF group were picked robotically (ProPick II, Digilab, Ann Arbor, MI) [16]. Gel spots were incubated at 37°C for 30 min in 50 mM NH4HCO3, dehydrated twice for 5 min each in 100 µL acetonitrile, and dried, and proteins were digested in-gel at 37°C overnight with 10 µL of trypsin solution (1% trypsin in 25 mM ammonium bicarbonate). Peptide mixtures (1-µL) obtained after tryptic digestion were purified with a ZipTip C18 column (Millipore) and reconstituted with 0.4% acetic acid. A 1 : 1 dilution of peptide solution with MALDI matrix solution (5 mg alpha-cyano-4-hydroxycinnamic acid per mL in 50% acetonitrile) was spotted on to the target plate and analyzed by matrix assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) using a MALDI-TOF/TOF ABI 4800 Proteomics Analyzer (AB Sciex, Foster City, CA). The Applied Biosystems software package included the 4000 Series Explorer (v.3.6 RC1) with Oracle Database Schema (v.3.19.0) and Data Version (3.80.0) to acquire and analyze MS and MS/MS spectral data. The instrument was operated in a positive ion reflectron mode with the focus mass set at 1700 Da (mass range: 850–3000 Da). For MS data, 1000–2000 laser shots were acquired and averaged from each protein spot. Automatic external calibration was performed by using a peptide mixture with the reference masses 904.468, 1296.685, 1570.677, and 2465.199. Following MALDI MS analysis, MALDI MS/MS was performed on several (5–10) abundant ions from each protein spot. A 1-kV positive ion MS/MS method was used to acquire data under postsource decay (PSD) conditions. The instrument precursor selection window was ±3 Da. Automatic external calibration was performed by using reference fragment masses 175.120, 480.257, 684.347, 1056.475, and 1441.635 (from precursor mass 1570.700) [32, 33].

AB Sciex GPS Explorer (v.3.6) software was employed in conjunction with MASCOT (v.2.2.07) to search the UniProt human protein database (last accessed: June 7, 2015; 87,656 sequences 35,208,664 residues) by using both MS and MS/MS spectral data for protein identification [33]. Protein match probabilities were determined by using expectation values and/or MASCOT protein scores. The MS peak filtering included the following parameters: a mass range of 800 Da to 3000 Da, minimum S/N filter = 10, mass exclusion list tolerance = 0.5 Da, and mass exclusion list for some trypsin and keratin-containing compounds included masses (Da) 842.51, 870.45, 1045.56, 1179.60, 1277.71, 1475.79, and 2211.1. The MS/MS peak filtering included the following parameters: minimum S/N filter = 10, maximum missed cleavages = 1, fixed modification of carbamidomethyl (C), variable modifications due to oxidation (M), precursor tolerance = 0.2 Da, MS/MS fragment tolerance = 0.3 Da, mass = monoisotopic, and peptide charges = +1. The significance of a protein match, based on the peptide mass fingerprint (PMF) in the MS and the MS/MS data from several precursor ions, is presented as expectation values ().

Protein spots (|≥2| fold change) identified with low confidence by MALDI MS/MS (protein score <62) were submitted for analysis by LTQ OrbiTrap Velos (ThermoFisher, Waltham, MA).

2.5. Functional Analysis and Multivariate Adaptive Regression Splines (MARS) Modeling

The protein datasets were assessed by using ingenuity pathway analysis (IPA, Ingenuity Systems®). IPA retrieves biological information from the literature—such as gene name, subcellular location, tissue specificity, function, and association with disease—and then integrates the identified proteins into networks and signaling pathways with biological interpretation and significance [34]. An “-value” was calculated by estimating the probability of a random set of proteins having a frequency of annotation for that term greater than the frequency obtained in the real set, and a significance threshold of 10−3 was used to identify significant molecular functions and biological processes [33]. With these parameters, we were able to highlight the most informative and significantly over-represented gene ontology terms in the dataset [35].

For MARS modeling, log2-transformed values of normalized spot volumes for all spots from 120 gels were exported from SameSpots in to Excel and analyzed by using R and SPSS ver.20 software. For modeling the disease state specific response, a stringent cut-off was applied; differentially abundant protein spots were first screened by -test/Welch’s correction and then Benjamini-Hochberg test was employed at (|≥1.5| fold change). MARS was employed to model changes in multiple variables for distinguishing between infection and disease status [31]. To avoid overfitting the data, we employed two approaches: (1) 10-fold cross-validation (CV), allowing the same number of maximum basis functions as were the differentially abundant protein spots at (with 1 max interaction term), and (2) testing/training approach in which 80% of the data was utilized for creating the model and the 20% of the remaining data was used to assess the fit of the model for testing dataset. The sensitivity and specificity of the identified models were validated by receiver operator characteristics (ROC) curves [31].

2.6. Enzyme-Linked Immunosorbent Assay (ELISA) and Biotin-Switch Assay

A new batch of PBMC samples from HF and NH subjects ( per group) were lysed by sonication in cold PBS and the protein concentrations were evaluated by the Bradford method (Bio-Rad). A sandwich ELISA kit was used to quantify the vinculin (VCL) abundance, following the manufacturer’s instructions (Cloud-Clone Corp, Houston TX; sensitivity: ≥30-pg/mL). Briefly, PBMC lysates (5-µg/100 µL/well) were loaded onto 96-well plates precoated with VCL-specific antibody. After overnight incubation at 4°C, plates were aspirated and sequentially incubated with biotin-conjugated anti-VCL 2nd antibody (1 : 100 dilution), avidin-conjugated horseradish peroxidase (HRP) (1 : 100 dilution), and TMB substrate. The change in absorbance was measured at 450 nm by using a Spectramax 190 spectrophotometer (Molecular Devices, Sunnyvale, CA). The plates were washed between each reagent addition and a standard curve was prepared by using recombinant VCL protein (0–5000 pg/mL).

THBS1 abundance in PBMC lysates was quantified by using a sandwich ELISA kit (R&D Systems, Minneapolis, MN; sensitivity: ≥350-pg/mL). In brief, PBMC lysates (5 µg/50 µL/well) were loaded with 100 μL of the provided assay diluent onto 96-well plates precoated with THBS1-specific monoclonal antibody and incubated overnight at 4°C. The plates were washed and incubated with HRP-conjugated THBS1 polyclonal antibody before addition of the TMB substrate. Absorbance was measured at 450 nm, and a standard curve was prepared by using 0–1000 ng/mL recombinant THBS1 protein.

The levels of S-NO modified VCL and THBS1 in PBMC lysates were determined by performing a biotin-switch assay followed by ELISA. Briefly, PBMC lysates were made as above, free SH (thiol) groups were blocked, protein S-NO bonds were present in the sample cleaved, and the newly formed SH groups were biotinylated using an S-Nitrosylated Protein Detection Assay Kit (Cayman Chemicals, Ann Arbor, MI) according to instructions provided by the manufacturer. The 96-well plates were coated for 2 h at room temperature with anti-VCL (Cloud-Clone Corp) or anti-THBS1 (R&D Systems) antibody (1 : 1000 dilution in Tris-buffered saline, TBS). Plates were then blocked for 2 h at room temperature with 5% BSA in TBS, washed three times with TBS, and incubated for overnight at 4°C with biotin-derivatized protein lysates (5 µg/100 µL/well). Plates were washed to remove the unbound proteins and then incubated for 30 minutes at room temperature with streptavidin-HRP conjugate (1 : 3000 dilution; BioLegend, San Diego, CA). Color was developed using the TMB substrate, and the change in absorbance reflecting the levels of biotin-bound S-NO modified VCL or THBS1 was measured by spectrophotometry.

2.7. Western Blotting

A 5 µg aliquot of each protein sample was resolved on 10% acrylamide gels and wet-transferred to PVDF membranes by using a vertical Criterion Blotter (Bio-Rad). Membranes were blocked for 1 hour with 5% nonfat dry milk (Lab Scientific, Highlands, NJ) in 20 mM Tris Base (pH 7.4) containing 150 mM NaCl and 0.1% Tween-20 (TBST). All antibody dilutions were made in 3% bovine serum albumin (Fisher Scientific, Pittsburgh, PA) in TBST. Membranes were sequentially incubated overnight at 4°C with polyclonal rabbit anti-THBS1 antibody (0.5 µg/mL dilution, Abcam, Cambridge, MA) and goat anti-rabbit HRP-conjugated secondary antibody (1 : 10,000 dilution, Southern Biotech, Birmingham, AL), and the signal was developed by using the Amersham ECL Plus system (GE Healthcare). Images were visualized and digitized by using the ImageQuant system (GE Healthcare).

3. Results

3.1. 2D-GE/MALDI MS Identification of Changes in PBMC Proteome in Heart Failure

A schematic of work flow is presented in Figure 1(a). We employed a saturation fluorescence approach using BODIPY FL-maleimide (BD, dye to protein thiol ratio of >60 : 1) that specifically labels protein thiols to give an uncharged product with no nonspecific labeling [17, 18]. BD-labeled protein isoelectric points were unchanged and mobilities were identical to those in the unlabeled state. The Typhoon Trio Variable Mode Imager has a linear dynamic range of over four orders of magnitude and was capable of detecting 5 fmol of BD-labeled protein in a gel spot at a signal-to-noise ratio of 2 : 1 [1719]. To ensure saturation labeling, protein extracts were analyzed for cysteine content and sufficient dye was added to achieve the desired excess of dye to thiol. This saturation fluorescence labeling method yielded high accuracy (>91%) in quantifying blinded protein samples [30] and, in a study that detected >1000 proteins across 6 experimental treatments, exhibited <9% CVs across triplicate runs.

The BD-labeled Asc+ and Asc PBMC lysates of NH controls () and HF subjects () were resolved by 2D-GE to obtain a disease-specific protein abundance and S-NO modification signature. Representative Asc+ and Asc gel images from each group are shown in Figure 1(b)((A)–(D)). All protein spots within the relative molecular sizes of 10 to 250 kDa after reduction and denaturation were detected. Some proteins may fall outside this size range and may have been missed; however, since all proteins were denatured and eventually reduced, we feel this is a minor limitation, no more so than the limited acetonitrile elution range and data dependent modes typically used in mass spec-centric approaches.

We identified 93 differentially abundant protein spots (59 upregulated, 34 downregulated, and fold change: |≥1.5|, ) and 111 differentially S-NO modified protein spots (63 low RoR, 48 high RoR, and fold change: |≥1.5|, ) in HF (versus NH) subjects with high confidence (Table 1). The changes in abundance and Cys-S-NO modification frequency of the protein spots in HF subjects ranged from 3.00-fold to −3.61-fold and −5.05-fold to 3.76-fold, respectively (Figure 3(a)). Further, 71 protein spots were changed in both abundance and Cys-S-NO levels, while 22 and 36 protein spots were uniquely changed in abundance or S-NO modification levels, respectively, in HF subjects (Figure 3(b)). The protein spots that were changed in abundance or in Cys-S-NO levels were predicted to be localized mostly in the cytoplasm (71%), with the rest distributed to the nucleus (5%), plasma membrane (10%), or extracellular space (7%) (Figure 3(c)). Top differentially expressed (Figure 3(d)) and S-NO-modified (Figure 3(e)) protein spots in HF subjects, which were identified by ingenuity pathway analysis (IPA), are presented. Note that KRT1, THBS1, ATP5A1, and MYO9A were increased in abundance as well as S-NO modification levels, while VCL, HBB, and ATP5B were decreased in abundance and S-NO modification levels in HF subjects.

2D-GE dataMALDI MS data2ASC/ASC+ (ΔSNO) ratio1Abundance (ASC+)3S-NO ROR
Spot numberpIMW (kD)Plate numberProtein and gene nameAccession numberMS (LC MS/MS) ID protein scoreNHHFHF versus NHHF versus NH

526.39108F1Vinculin GN=VCLP182067091.14−1.03−1.881.83
546.57108H14Vinculin GN=VCLP18206-211801.081.09−3.293.58
576.68107H15Vinculin GN=VCLP18206-21130−1.03−1.06−3.092.91
586.80107F20Vinculin GN=VCLP18206-21210−1.011.04−3.613.76
596.94107F21Vinculin GN=VCLP1820611701.011.04−3.273.39
607.09105C14FAM212B GN=FAM212BQ9NTI7291.04−1.06−2.382.25
637.53997Vinculin GN=VCLP182062361.12−1.24−1.541.24
796.4896F22Albumin GN=ALBP02768190−1.28−1.14−2.031.78
816.6294F23Keratin, type I cytoskeletal 9 GN=KRT9P35527188−1.18−1.23−2.371.93
926.9387F24Filamin-A GN=FLNAQ5HY54384−1.17−1.56−1.20−1.31
956.8187G2Filamin-A GN=FLNAQ5HY54399−1.19−1.22−2.021.66
994.5484G4Glucose-regulated 78 kDa protein GN=HSPA5P110218491.011.29−1.612.08
1026.6883G5Filamin-A GN=FLNAQ5HY54210−1.26−1.32−1.641.24
1036.4182H21Filamin-A GN=FLNAP21333238−1.28−1.03−1.681.63
1046.5282I20Gelsolin GN=GSNP06396-2182−1.32−1.11−1.721.55
1245.2168G6Heat shock 71 kDa protein GN=HSPA8P11142-23251.04−1.01−1.521.51
1279.0968G7Fibrinogen alpha chain GN=FGAP02671-2621.07−1.651.54−2.53
1315.3568G8Keratin, type I cytoskeletal 10 GN=KRT10P13645296−1.15−1.08−1.721.59
1368.8468E6Transketolase GN=TKTB4E022189−1.03−1.881.84−3.46
1415.97631Serum albumin GN=ALBH0YA55167−
1424.5163G9Tropomyosin 3 GN=TPM3Q5VU597431.011.34−1.832.46
1456.4160A1Serum albumin GN=ALBH0YA55245−1.59−1.28−1.04−1.24
1466.7860C15Serum albumin GN=ALBP02768116−1.00−1.421.32−1.88
1545.3459H24Actin, cytoplasmic 1 GN=ACTBP60709391−1.43−1.07−1.551.44
1805.1454J11Actin, cytoplasmic 1 GN=ACTBP60709353−1.141.18−1.762.07
1855.5053K19Actin, cytoplasmic 1 GN=ACTBP607093651.28−1.161.41−1.63
1977.4851G12Fibrinogen beta chain GN=FGBP02675157−1.14−1.07−1.531.43
2044.2950G13Nucleosome assembly protein 1 GN=NAP1L1F8VRJ2791.21−1.07−1.741.62
2058.5050C16Fibrinogen beta chain GN=FGBP02675336−1.11−1.181.00−1.18
2224.7147J13ATP synthase subunit beta GN=ATP5BH0YH81302−1.061.20−1.922.30
2418.7945J1Transcription factor 4 GN=TCF4 (integrin-linked protein kinase GN=ILK)H3BME836 (305)−1.73−1.16−1.681.45
2616.5741101POTE ankyrin domain family member FA5A3E0121−1.471.16−1.351.57
2627.6841I5Elongation factor Tu, mitochondrial GN=TUFMP49411195−1.52−1.04−1.581.52
2644.8641J18Actin, cytoplasmic 1 GN=ACTBP60709336−1.051.06−1.491.58
2676.414116Actin, cytoplasmic 2, N-terminalF5H0N0106−1.191.33−1.151.53
2728.7041B9Myeloperoxidase GN=MPOP05164-283−1.30−1.471.22−1.79
3034.5438B10Actin, cytoplasmic 1 GN=ACTBP60709911.171.18−1.321.55
3297.1735I10DnaJ homolog subfamily B 11 GN=DNAJB11H7C2Y541−1.25−1.461.17−1.70
3355.5535D6Actin, cytoplasmic 1 GN=ACTBP60709225−1.14−1.091.88−2.04
3375.8134D7Actin, cytoplasmic 1 GN=ACTBP60709456−1.20−1.061.64−1.74
3396.3334105Tubulin beta chain GN=TUBBQ5JP53121−1.28−1.381.19−1.64
3436.7234B13Actin, cytoplasmic 1 GN=ACTBP6070997−1.17−1.361.26−1.71
3443.6333A2Stromal interaction molecule 2 GN=STIM2Q9P246331.43−1.181.98−2.34
3487.1133D8Phosphoglycerate kinase GN=PGK1B7Z7A954−1.23−1.921.49−2.86
3584.5631G24Tropomyosin 1 alpha isoform 7 GN=TPM1D9YZV85151.201.13−1.521.72
3737.3230H1Annexin A1 GN=ANXA1P04083200−1.18−2.15−1.13−1.91
3844.0229L10LVV-hemorphin-7 GN=HBBF8W6P547−1.091.57−1.983.12
3855.7229102Vimentin GN=VIMF5H288171−1.22−1.361.20−1.63
3956.8527E8Keratin, type II cytoskeletal 2 GN=KRT2P35908381−1.46−1.651.70−2.80
3974.0127J23Tropomyosin alpha-4 chain GN=TPM4P679361011.071.41−1.582.22
4006.7026L2Thrombospondin-1 GN=THBS1P07996769−−1.91
4047.512617Actin, cytoplasmic 1, N-terminal GN=ACTBB4DW521331.23−1.091.91−2.08
4068.0826K1Uncharacterized protein FLJ46347Q6ZRH936−1.07−1.161.88−2.18
4117.98265Myosin-IXa GN=MYO9AH3BMM1461.09−1.272.26−2.86
4244.6925F15Tropomyosin alpha-4 chain GN=TPM4P679369261.731.181.85−1.57
4258.632512Peptidyl-prolyl cis-trans isomerase A GN=PPIAP62937110−1.36−1.171.46−1.71
4316.7024H3Haloacid dehalogenase-like hydrolase domain-containing protein 2 GN=HDHD2K7ER15102−1.20−1.271.42−1.80
4519.3323F16Glyceraldehyde-3-phosphate dehydrogenase GN=GAPDHE7EUT4711.02−1.361.12−1.52
4616.9822B17Annexin A1 GN=ANXA1P040833441.23−1.071.55−1.65
4764.7421D10Actin, cytoplasmic 1 GN=ACTBP607092261.051.221.51−1.24
4918.5820B18Thrombospondin-1 GN=THBS1P079961381.20−1.202.45−2.95
5016.7820H6Peroxiredoxin-6 GN=PRDX6P30041237−1.08−1.481.51−2.23
5058.2220I14Thrombospondin-1 GN=THBS1P079961971.061.071.52−1.42
5076.6120H7Growth factor receptor-bound protein 2 GN=GRB2P62993-280−1.01−1.141.48−1.68
5098.7220L3Thrombospondin-1 GN=THBS1P07996418−1.03−1.292.74−3.53
5117.3020D14Carnitine O-palmitoyltransferase 1 GN=CPT1AP5041632−1.15−1.031.65−1.70
5144.1020E9Transcriptional repressor protein YY1 GN=YY1H0YJV7471.011.27−1.431.82
5155.2619L4Apolipoprotein A-I GN=APOA1P026473521.061.111.56−1.40
5184.2919C21Vimentin GN=VIMB0YJC42031.131.37−1.171.60
5249.3419108Keratin, type I cytoskeletal 10 GN=KRT10P13645286−1.02−1.471.42−2.08
5308.6119L11Keratin, type II cytoskeletal 1 GN=KRT1P04264551.42−1.353.00−4.04
5496.9419J5Glutathione GN=GSH (Ras-related protein Rab-14 GN=RAB14)P0720371 (288)1.10−1.131.57−1.78
5635.9918109Actin, cytoplasmic 2, N-terminal GN=ACTBI3L1U9137−1.531.07−1.601.71
5676.9318C22Glutathione S-transferase P GN=GSTP1P09211286−1.02−1.301.26−1.64
5683.6218E10Transcriptional repressor protein YY1 GN=YY1H0YJV7391.47−1.221.83−2.24
5744.6517C23Tubulin beta-1 chain GN=TUBB1Q9H4B7391.211.28−2.092.66
5883.8817A8Alpha-actinin-1 GN=ACTN1 (Alpha actinin 1 GN=ACTN1)H0YJ1150 (222)1.441.24−1.281.59
5917.5517E12Heat shock 70 kDa protein 1A/1B GN=HSPA1AE7EP11431.01−1.071.43−1.52
5924.3817106Myosin regulatory light chain 12B GN=MYL12BO149503201.431.62−1.712.78
5934.4717C24Actin, cytoplasmic 1 GN=ACTBP60709651.631.75−1.662.91
5958.2717A9Protein S100-A8 GN=S100A8P05109601.59−1.071.65−1.76
6034.7616A10Annexin A5 GN=ANXA5D6RBL5111−1.20−1.371.13−1.55
6055.6416110ATP synthase subunit alpha GN=ATP5A1A8K09295−1.03−1.00−1.021.01
6076.7116B20Actin-related protein 2/3 complex subunit 3 GN=ARPC3O15145501.061.141.64−1.43
6124.1916K21Myosin regulatory light chain 9 GN=MYL9P248442331.191.381.62−1.17
6134.6116D17Actin, cytoplasmic 2 GN=ACTG1P63261611.451.211.78−1.47
6235.1616A12Actin, cytoplasmic 2, N-terminal GN=ACTG1K7EM381301.301.291.87−1.45
6275.47153Annexin A6 GN=ANXA6E5RIU8103−−1.26
6283.7915E14Myosin light polypeptide 6 GN=MYL6F8VZV53021.301.321.121.18
6294.3515A13Actin, cytoplasmic 1 GN=ACTBP60709651.241.321.151.14
6308.0515K6Peptidyl-prolyl cis-trans isomerase A GN=PPIAP62937199−1.04−1.18−1.10−1.07
6329.0215I15Peptidyl-prolyl cis-trans isomerase A GN=PPIAP62937235−1.01−1.12−1.201.07
6405.121513Actin, cytoplasmic 1, N-terminal GN=ACTBG5E9R01931.451.401.82−1.30
6424.2115E15Actin, cytoplasmic 1 GN=ACTBP607091391.051.25−1.311.64
6447.711521Keratin, type I cytoskeletal 10 GN=KRT10P13645471.161.32−1.071.41
6463.9815H9Myosin light polypeptide 6 GN=MYL6F8VZV53691.161.41−1.391.97
6488.3715D1Bestrophin-3 GN=BEST3 (dermcidin GN=DCD)A8MVM342 (160)1.171.981.291.53
6574.7915A14Actin, cytoplasmic 1 GN=ACTBP607091081.251.121.62−1.44
6624.6514A16Actin, cytoplasmic 1 GN=ACTBP607092631.551.621.65−1.02
6647.0114D19Actin, cytoplasmic 2, N-terminal GN=ACTG1K7EM38411.531.091.29−1.18
6654.4514A17Actin, cytoplasmic 1 GN=ACTBP607092331.561.161.51−1.30
6663.8214B22Mitochondrial carrier homolog 1 GN=MTCH1Q9NZJ7-3321.341.40−1.011.42
6718.6614B23Bestrophin-3 GN=BEST3A8MVM3401.211.432.00−1.40
6734.0314B24Isoform H14 of Myeloperoxidase GN=MPOP05164-2288−1.161.18−1.481.76
6835.0113A22Histone H4 GN=HIST1H4AP628052421.01−1.091.44−1.56
6907.9213L13Hemoglobin subunit beta GN=HBBP68871384−1.15−1.121.50−1.68
7037.7212D3LVV-hemorphin-7 (fragment) GN=HBBF8W6P541−1.131.09−1.491.63
7066.7012E16Protein S100-A11 GN=S100A11P31949260−1.391.27−1.752.22
7184.5311C4Ras-related protein Ral-B GN=RALB (actin cytoplasmic 2 GN=ACTG1)F8WEQ648 (155)1.20−1.301.64−2.14
7324.7211C6Thrombospondin-1 GN=THBS1P079961151.61−2.022.50−5.05
7374.0010D20ATP synthase subunit alpha GN=ATP5A1K7EQT2173−1.16−1.902.40−4.57
7383.8810D21Keratin, type II cytoskeletal 1 GN=KRT1P04264961.07−1.461.85−2.70
7404.860C7Urea transporter 1 GN=SLC14A1K7EJ54391.33−1.351.78−2.40
7444.40023Ras-related protein 1b GN=RAP1BB4DQI858−1.02−1.301.81−2.35
7594.8215D22Actin, cytoplasmic 2, N-terminal GN=ACTG1K7EM382631.271.371.73−1.27
7614.8216D23Keratin, type II cytoskeletal 1 GN=KRT1P042647891.241.311.62−1.24
7624.9116L14Actin, cytoplasmic 2 GN=ACTG1P632612211.341.181.69−1.44
7635.7320A24Actin, cytoplasmic 1 GN=ACTBP60709416−1.06−1.091.89−2.05
7695.3814B1Actin, cytoplasmic 1 GN=ACTBC9JUM1441.07−1.051.59−1.67
7725.3713B2Histone H4 GN=HIST1H4AP62805193−1.36−1.361.13−1.54
7743.7216J7Calmodulin GN=CALM1P62158367−1.111.47−1.512.23
7794.6328D24Actin, cytoplasmic 1 GN=ACTBP607094281.161.21−1.281.55
7814.6127E1Actin, cytoplasmic 1 GN=ACTBP607093421.041.01−1.071.08
7965.2913E19Keratin, type II cytoskeletal 1 GN=KRT1P042641271.29−1.702.35−4.00
7975.3413E20Keratin, type II cuticular Hb3 GN=KRT83P783851651.08−1.111.59−1.77
8046.9610E21LVV-hemorphin-7 (fragment) GN=HBBF8W6P51221.261.36−1.401.90
8088.1111L6Platelet basic protein GN=PPBPP02775901.431.19−1.381.64
8258.6572C8Lactotransferrin delta GN=LTFP02788-2147−1.44−1.651.51−2.49
8548.7467C9Kaliocin-1 GN=LTFE7EQB246−1.09−1.501.22−1.83
8664.8810C10S100-A6 protein GN=S100A6P06703391.46−1.121.94−2.18
8674.910C11LVV-hemorphin-7 GN=HBBF8W6P5651.261.161.50−1.29
8683.5916I18Calmodulin GN=CALM1P62158343−1.011.27−1.702.16
8703.6416K10Calmodulin GN=CALM1 (calmodulin GN=CALM1)E7ETZ063 (215)1.451.60−1.342.15
8713.6916K11Calmodulin GN=CALM1E7ETZ01951.331.31−1.491.95
8773.8055B4Stromal interaction molecule 2 GN=STIM2Q9P246391.31−1.301.69−2.20
8796.8711E23LVV-hemorphin-7 GN=HBBF8W6P5213−1.021.20−1.401.69
8897.8070H12Fibrinogen alpha chain GN=FGAP02671-2165−1.04−1.321.87−2.48
8904.9416E3Actin, alpha 1, skeletal muscle GN=ACTA1Q5T8M81241.241.291.31−1.01
8915.0315E4Actin, cytoplasmic 2, N-terminal GN=ACTG1K7EM381131.231.141.82−1.59
8927.5713E5Annexin A2 GN=ANXA2H0YKV8109−1.321.17−1.491.75
8974.3014B6Actin, cytoplasmic 1 GN=ACTBP607092421.151.331.51−1.14
9018.6413L7Hemoglobin subunit beta GN=HBBP688712541.17−1.041.56−1.62
9028.6013L8Hemoglobin subunit beta GN=HBBP688713501.02−1.041.61−1.67
9038.6013L9Hemoglobin subunit beta GN=HBBP688713531.181.021.95−1.90
9048.2613L15Hemoglobin subunit beta GN=HBBP688713491.07−1.021.72−1.76
9058.2913K23Hemoglobin subunit beta GN=HBBP68871330−1.09−1.071.59−1.70
9114.6910I19SH3 domain-binding glutamic acid-rich protein 3 GN=SH3BGRL3Q9H2993541.39−1.201.59−1.91

The PBMC protein samples from normal healthy (NH, ) and heart failure (HF, ) subjects were incubated with (Asc+) or without (Asc) ascorbate and resolved by 2D-GE approach. Gels were labeled with BODIPY FL N-(2-aminoethyl) maleimide, images were analyzed with SameSpotst software, and normalized spot volumes were used for comparison. Proteins spots with ≥|1.5| fold change in abundance or S-nitrosylation level () in HF subjects were subjected to MALDI-TOF MS/MS analysis and those identified with high confidence (score >62) are shown with . Some of the protein spots were also identified by LC MS/MS and this information is presented in brackets in protein and gene name and ID score columns.
1Ratiometric calculation from BODIPY-fluorescence units in Asc+ aliquots (normal versus experimental) was conducted for quantifying the differential abundance of protein spots (Δprotein abundance = Asc+ HF/Asc+ NH).
2The S-NO modification levels were quantified by calculation of the ratio of fluorescence units from Asc aliquots (ΔS-NO = Asc HF/Asc NH).
3The ratio of ratios, that is, ΔS-NO/Δprotein abundance = [Asc HF/Asc NH]/[Asc+ HF/Asc+ NH], was calculated to obtain the change in S-NO levels normalized for protein abundance. As S-NO modification inhibits the Cys-BODIPY fluorescence, a negative (green) and a positive (red) RoR value would indicate an increase and decrease in S-NO levels, respectively, in HF (versus NH) subjects.
3.2. Pathway Network Analysis of the Disease-Associated Proteome Signature

The protein abundance and S-NO modification datasets from HF versus NH controls (Table 1) were submitted to IPA to determine molecular and biological functions, as well as the important pathways and networks involved in HF risk. IPA analysis of the differentially abundant proteome dataset predicted a putative increase in platelet aggregation ( score: 1.432), phagocyte chemotaxis/migration ( score: 1.091, value ), and free radical production ( score: 1.491, value ) with a decline in leukocyte/neutrophil activation and fatty acid metabolism in HF development (Figures S1A and S1B in Supplementary Material available online at The molecular and cellular function annotation of the differentially abundant proteome dataset predicted an increase in cell death ( score: 1.989, 21 molecules, and value ) and a decline in cell survival and cell viability ( score: −0.809, 11 molecules, and value ) in HF subjects (Figure S2).

IPA analysis of the differential S-NO proteome dataset showed increased S-NO-modification of several molecules predicted to be involved in migration of phagocytes (Figure S3). However, increased S-NO-modification of other molecules was predicted to inhibit cell spreading and development of blood vessels in HF subjects (Figure S3). Likewise, we noted increased S-NO-modification of several molecules predicted to be involved in inhibition of apoptosis and activation of organismal death and free radical production in HF subjects (Figure S4). These data suggested that changes in abundance and S-NO modification serve as an important mechanism in regulating inflammation and cellular survival in HF.

3.3. MARS Modeling Identifies Proteins Predictive of HF

We performed MARS analysis on our proteome dataset to develop a classification model (Figures 4 and 5). MARS is a nonparametric regression procedure that creates models based on piecewise linear regressions. It searches through all predictors to find those most useful for predicting outcomes and then creates an optimal model by a series of regression splines called basis functions [36, 37]. For this, MARS uses a two-stage process; the first half of the process involves creating an overly large model by adding basis functions that represent either single variable transformations or multivariate interaction terms. In the second stage, MARS successively deletes basis functions, starting with the lowest contributor in order of least contribution to the model until the optimum model is reached. The end result is a classification model based on single variables and interaction terms that will optimally determine class identity [36, 37].

Inputs to the model were the log2-transformed values for protein spots that were differentially abundant (31 spots) or S-NO-modified (42 spots) in HF subjects with respect to NH controls at with B-H correction. We assessed the model accuracy using the prediction success rate and the ROC curves. The CV and 80/20 approaches identified 12 and 8 protein spots, respectively, with high importance (score >20) for creating the MARS model that permits detecting differences in abundance between the NH controls and the HF subjects (Figures 4(a) and 4(b)). The prediction success showed that the CV and 80/20 models fitted perfectly (AUC/ROC: 1.00) on the training dataset. On the testing dataset, the CV model exhibited higher prediction efficiency (AUC/ROC: 0.917) than the 80/20 model (AUC/ROC: 0.828), as is shown in Figures 4(c) and 4(d).

Likewise, the CV and 80/20 approaches identified 5 and 6 protein spots, respectively, detecting differences in S-NO modification between NH controls and the HF subjects with high importance (score >20) for creating the MARS model (Figures 5(a) and 5(b)). The prediction success showed the CV and 80/20 models fitted perfectly on the training dataset (AUC/ROC: 1.00) and by >75% on the testing dataset (AUC/ROC: 0.75 for CV and 0.857 for 80/20) (Figures 5(c) and 5(d)). These analyses suggested that PBMC changes in abundance and S-NO modification of the selected protein spots will have high specificity and sensitivity in predicting the risk of HF.

3.4. Verification of BD-Labeling/2D-GE Results

Changes in abundance of four proteins, ACTB, ATP5B, VCL, and THBS1, were predictive of the risk of HF with high efficacy by IPA analysis as well as the CV and 80/20 MARS models; these proteins were also noted to be differentially S-NO modified in HF subjects (Table 1). We utilized a different set of PBMC samples from NH and HF subjects (/group) and employed ELISA/Western blotting and biotin-switch assay, respectively, to verify the changes in abundance and S-NO levels of two proteins in HF subjects (Figures 6 and 7).

Human vinculin is a 117 kDa protein. Our BD/2D-GE approach had identified six VCL polypeptides (spot # 52, 54, 57, 58, 59, and 63; pI: 6.39–7.53) that were close to full-length protein in size (MW: 99–108 kDa) and decreased in abundance as well as S-NO modification levels in HF subjects (Table 1). ELISA and biotin-switch/ELISA showed 2.4-fold and 49% decline in VCL abundance (Figure 6(a), ) and S-NO modification level (Figure 6(b), ), respectively, in PBMCs of HF subjects when compared to that noted in NH controls. These data confirmed that our approach of BD-labeling/2D-GE provided a sensitive measure of proteomic changes in HF.

Human thrombospondin 1 is a 130 kDa protein. Our BD/2D-GE approach had identified five THBS1 polypeptide fragments (spot # 400, 491, 505, 509, and 732; pI: 4.72–8.72) that were increased in abundance and S-NO modification levels in HF subjects (Table 1). The 2D-GE image of one of the five THBS1 spots from representative Asc+ and Asc NH (Figure 7(a), panels (A) and (C)) and HF (Figure 7(a), panels (B) and (D)) PBMCs is shown. Thus, the BD/2D-GE data suggested that fragmented THBS1 was increased in abundance and S-NO modification in HF subjects. The representative Western blotting data for the 130 kDa THBS1 molecule in PBMCs of HF subjects versus NH controls showed that the intact THBS1 was indeed absent or present at very low concentrations in HF subjects (Figure 7(b)). The sandwich ELISA using a combination of antibodies that preferably detect 130 kDa THBS1 showed that the full-length THBS1 was significantly decreased in PBMCs of HF subjects (Figure 7(c), ). These data, thus, confirmed that THBS1 was fragmented (as noted by 2D-GE) in HF subjects.

Because biotin-switch assay was coupled with sandwich ELISA for full-length THBS1, we did not detect the differences in S-NO levels of fragmented THBS1 between NH versus HF subjects (Figure 7(d)). An ELISA specific for the fragmented THBS1 polypeptide will be useful to distinguish the abundance and S-NO levels of functional versus cleaved THBS1 in the PBMCs of patients to predict the risk of heart failure.

4. Discussion

In the present study, we have performed a high throughput proteomic analysis of PBMCs from 30 heart failure patients in comparison with 30 healthy subjects. We ran 120 2D gels toresolve the protein samples and utilized BODIPY FL N-(2-aminoethyl) maleimide labeling as a novel method to detect changes in abundance and S-NO modification in PBMC samples. Of the 635 protein spots that were detected on 2D-gels, 93 and 111 protein spots (|≥1.5-fold|, ) were found to be consistently differentially abundant (range 3-fold to −3.6-fold) or S-NOmodified (range: 3.76-fold to −5.05-fold) in HF subjects, and these protein spots were identified by MALDI-TOF MS analysis (Table 1). The finding that many of the differentially abundant protein spots were S-NO modified suggested that S-NO serves as a mechanism for regulating protein function and turnover in HF.

As the NIH/NIAID-funded Clinical Proteomics Center for Infectious Diseases and the NIH/NHLBI-funded Proteomics Center in the US, we have used the BODIPY FL-mal saturation fluorescence method for differential proteomic analysis of >2000 protein samples of diverse origin and found the assay to yield highly reproducible and quantitative results. Our protocol involved quantitation of cysteine content in samples, ensuring that the dye to thiol ratio exceeds 50 : 1 to achieve saturation dye concentration [17, 18]. Further, by using a panel of proteins including yeast enolase, bovine alpha-lactalbumin A, bovine carbonic anhydrase II, and horse myoglobulin that consist of 1, 8, 0, and 0 cysteine residues, respectively, we showed that BODIPY FL-mal (a) efficiently labels proteins in presence of thiourea at pH 7.2–8.0, and (b) dye-binding is highly specific within dye to thiol concentration ratio in the range if 5–200 : 1 and sensitive with detection limit of 0.6 fmol per cysteine in a protein spot. No detectable binding was observed with proteins containing no cysteine. Moreover, the BD labeling was linear over 4 orders of magnitude of concentration with high reproducibility in replicates (CoV: 1.9–9.4% for replicates and multiple test runs) and did not interfere with mobility of the proteins on gels and identification by mass spectrometry [18]. The protocol also employed precautions used by others in the literature, namely, neocuproine added where appropriate, sample prep (before covalent modification, locking in S-NO status) in the dark and cold, and minimal time before S-NO reduction and covalent modification of Cys-SH. The latter precaution is an improvement over the conventional approaches. Importantly, like biotin-switch assay, BODIPY FL-Mal utilizes sulfhydryl-based chemistry, requiring the thiolate ion for reaction, and is, therefore, acutely sensitive to the pH during alkylation. We precisely control the pH of the alkylation reaction. Thus, we surmise that the BD FL-mal labeling provides a powerful approach in quantification of changes in protein abundance and cysteinyl-S-nitrosylation in a variety of complex protein samples in diverse disease processes.

IPA analysis of the differentially abundant proteome dataset at the disease and functionallevel suggested the activation of phagocyte chemotaxis/migration and free radical production alongside a decrease in fatty acid metabolism (↑ACTB, ↓ALB, ↑APOA1, ↑ANXA1, ↑CPTA1, ↓GSN, ↓HBB, ↓HSPA8, ↑LTF, ↑PRDX6, ↑S100A8, and ↑THBS1) and an increase in platelet aggregation (↓ALB, ↑FGA, ↓FGB, ↓GSN, ↑RAP1B, and ↑THBS1) with HF development (Figure S1). Disease and functional network analysis of the differential abundance proteome dataset also suggested increased cell death response in HF patients (Figure S2). Interestingly, several of the proteins involved in phagocytes’ migration (e.g., ANXA1, THBS1, and S100A8), cell death (e.g., YY1, RALB, RAP1B, and LTF), fatty acid metabolism (e.g., CPT1A, PRDX6, LTF, and APOA1), or leukocyte/neutrophil activation were increased in abundance as well as in S-NO levels. How increased S-NO modification contributes to activation (phagocyte migration and cell death) and downregulation (fatty acid metabolism) of specific pathways is not known. Nevertheless, our observations allow us to propose that Cys-S-nitrosylation serves an important function in regulating immune responses and cell survival in HF development. Further studies will delineate the processes of selective targeting of proteins for S-NO modification and its effect on functional activity of the proteins. It is intriguing to note that (a) phagocytes activation and a decline in fatty acid metabolism where both of which were not spared from S-NO modification were differentially regulated in HF; (b) recent studies have indicated that upregulation of glucose metabolism promotes proliferation and activation of proinflammatory macrophages [38]. Our findings provide the first indication that a metabolic shift potentially contributes to proinflammatory state in progressive HF, to be verified in future studies.

Others have shown that S-NO formation results in a decline in the bioavailability of nitric oxide required for intracellular Ca2+ flux, the myofilament response to Ca2+, and thereby can influence the systolic and diastolic performance of the myocardium [39]. It is suggested that NO/cGMP-dependent cardiac homeostasis is adversely influenced by phosphodiesterase 5 (PDE5) in the hypertrophied heart [4042]; S-NO of PDE5 promotes its degradation by ubiquitination pathway [42]. Thus, S-NO may have beneficial as well as harmful role in the context of HF development.

MARS modeling by two different approaches indicated 14 abundant and 9 S-NO modified protein spots in the PBMC dataset to be predictive of HF development. Of these, ACTB, ATP5B, THBS1, and VCL were identified to be differentially expressed by both CV and 80/20 MARS models with high predictive efficacy. We validated the relative change in abundance of VCL and THBS1 in a second set of PBMCs from HF patients, and these proteins merit further discussion in the context of HF. Thrombospondin family consists of multimeric, multidomain calcium-binding glycoproteins that act as regulators of cell-matrix associations as well as interacting with other ECM molecules affecting their function [43]. The expression of THBS1 (and -2 and -4 isoforms) was increased in hypertensive heart disease [43]. Studies using a murine model of THBS1 genetic deletion suggested that, in cardiac remodeling after myocardial infarction, THBS1 limits the infarct expansion of the noninfarcted myocardium [44] and these benefits were delivered via activation of TGF-β, MMP inhibition, and CD47-mediated anti-inflammatory actions [45]. THBS2 and THBS4 isoforms have been shown to protect ECM adverse remodeling in ageing heart [46] and viral myocarditis induced HF [47]. Others have shown that THBS1 peptide antagonist prevented the progression of cardiac fibrosis and improved cardiac function by reducing TGF-β activity in a rat model of diabetic cardiomyopathy [48]. Our observation of increased abundance of 11–26 kDa fragments of THBS1 that were also S-NO modified in HF patients (Figure 7) suggested that THBS1 expression and catabolism was enhanced in HF patients. The finding of a significant decrease in full-length THBS1 (Figures 7(b) and 7(c)) was also in agreement with the observation of high rate of degradation and secretion of THBS1 during heart failure [49, 50]. A direct relationship between THBS1 secretion and increase in inflammation in aortic aneurysm is also noted [51]. These observations emphasize the context-dependent functions of THBSs in signaling TGF-β activation versus cardiac hypertrophy and heart failure. Yet, our observations of an increase in the abundance of several indicators of inflammation (discussed above), cardiac arteriopathy (↑APOA1, ↑FGA, ↑THBS1, ↑TKT, ↓TUBB1, value ), and hypertrophy (↑CPT1A, ↓GSN, ↑MYL9, ↑S100A6, ↓TPM1, value ), many of which (e.g., CPT1A, GRB2, HSPA1A/HSPA1B, and S100A6) were also increased in S-NO levels ( value ) in HF subjects, suggested that fragmented THBS1 is potentially a signaling molecule in cardiac remodeling/inflammatory processes in heart failure, to be validated in future studies.

Vinculin, among others, is a component of subsarcolemmal structures, also known as costameres, in striated muscle that circumferentially align with the Z-disk of the myofibrils, and functions to allow muscle adhesion to the ECM [52]. A splice variant of VCL (termed metavinculin, MVCL) is expressed in muscle and platelets. Several studies using cellular models (e.g., cardiomyocytes, fibroblasts) have indicated that VCL/MVCL mechanically couple the actin-based cytoskeleton to the sarcolemma and regulate focal adhesion turnover [53]. Our finding of a decline in VCL in PBMCs of HF patients is in alignment with the observations made in genetically modified mice depleted of VCL expression. The mice displayed thin-walled myocardium [54] while mice exhibited severe pressure overload induced hypertrophy and progressive LV dysfunction associated with abnormalities of Z-line structure in the myocardium [55]. The cardiac-specific VCL knockdown resulted in early development of ventricular tachycardia followed by cardiomyopathy and all mice died before 6 months of age [56]. The absence of cardiac VCL was associated with highly serrated intercalated disks that connect myocytes end-to-end and loosely arranged and disorganized mitochondria in cardiomyocytes [56]. Others have reported linkage of multiple mutations of VCL with dilated and hypertrophic forms of human cardiomyopathy [57, 58]. These studies show a clear linkage in alteration of VCL expression with cardiomyopathy and heart failure, emphasize the critical role of VCL/MVCL in maintenance of cardiac function, and provide us with impetus to evaluate peripheral VCL levels as a risk factor in heart failure development.

In summary, current study was focused on the S-NO modification and its impact on the pathophysiology in HF. Future studies will be required to investigate the interplay between protein nitrosylation and other cysteine-based PTM in heart failure. A number of other posttranslational modifications (PTMs), for example, acetylation, O‐GlcNAcylation, 3-nitrotyrosine, and carbonyls, have also been implicated in HF of diverse etiologies [59]. The pathophysiological significance of PTMs with a potential impact on protein misfolding, function, and ultimate disease outcomes in HF is recently reviewed in excellent review article [60]. Our proteome analysis of the PBMCs from HF patients showed differential abundance and S-NO modification of proteins involved in cell viability and production of reactive oxygen species and indicated the potential of THBS1 and VCL evaluation to be useful in the prediction for risk of heart failure.


The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

Competing Interests

The authors have no competing interests.


This work was supported, in part, by grants from the National Institutes of Health, National Heart Lung Blood Institute (R21 HL088230 and R01 HL094802 to NJG and N01-HV-00245 to Dr. A. Kurosky), and the National Institute of Allergy and Infectious Diseases (R21 AI07227 to NJG and Clinical Proteomics Center Grant no. HHSN272200800048C to Allan R. Brasier). The work was also, in part, supported by a Mini-Center Pilot Grant from the Institute for Human Infections and Immunity (IHII) and a bridging grant from the John Sealy Memorial Endowment Fund (JSMEF) at UTMB Galveston to Nisha Jain Garg. Sue-jie Koo is the recipient of a predoctoral fellowship from the UTMB McLaughlin Endowment, IHII. Maria P. Zago is supported by CONICET, Argentina. The authors are thankful to the Biomedical Resource Facility (BRF) and Mass Spectrometry Laboratory at the University of Texas Medical Branch at Galveston, for separations and mass spectrometric analysis.

Supplementary Materials

The proteome datasets were submitted to Ingenuity Pathway Analysis for identifying the networks and signaling pathways that were potentially disturbed in heart failure subjects. The differentially abundant proteins involved in disease and disorder network of inflammation (Figure S1), and disease and bio-function network of increased cell death and decreased cell survival (Figure S2) in heart failure (HF) subjects are presented. Further, the differentially S-NO-modified proteins involved in migration of phagocytes and inhibition of cell spreading (Figure S3) and in organismal death and cell apoptosis with production of free radicals (Figure S4) in HF subjects are presented.

  1. Supplementary Material


  1. A. Alwan, Global Status Report on Noncommunicable Diseases, World Health Organization, WHO Press, Geneva, Switzerland, 2011,
  2. World Health Organization, Chagas Disease: Control and Elimination. Report of the Secretariat, UNDP/World Bank/WHO, Geneva, Switzerland, 2010,
  3. D. M. Gopal and F. Sam, “New and emerging biomarkers in left ventricular systolic dysfunction—insight into dilated cardiomyopathy,” Journal of Cardiovascular Translational Research, vol. 6, no. 4, pp. 516–527, 2013. View at: Publisher Site | Google Scholar
  4. R. Schulz, M. Kelm, and G. Heusch, “Nitric oxide in myocardial ischemia/reperfusion injury,” Cardiovascular Research, vol. 61, no. 3, pp. 402–413, 2004. View at: Publisher Site | Google Scholar
  5. B. Lima, G. K. W. Lam, L. Xie et al., “Endogenous S-nitrosothiols protect against myocardial injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 15, pp. 6297–6302, 2009. View at: Publisher Site | Google Scholar
  6. K. Htet Hlaing and M.-V. Clément, “Formation of protein S-nitrosylation by reactive oxygen species,” Free Radical Research, vol. 48, no. 9, pp. 996–1010, 2014. View at: Publisher Site | Google Scholar
  7. T. Ahmad, M. Fiuzat, M. J. Pencina et al., “Charting a roadmap for heart failure biomarker studies,” JACC: Heart Failure, vol. 2, no. 5, pp. 477–488, 2014. View at: Publisher Site | Google Scholar
  8. K. Wasmer and L. Eckardt, “Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines,” Europace, vol. 13, no. 10, pp. 1368–1374, 2011. View at: Publisher Site | Google Scholar
  9. J.-J. Wen, M. Dhiman, E. B. Whorton, and N. J. Garg, “Tissue-specific oxidative imbalance and mitochondrial dysfunction during Trypanosoma cruzi infection in mice,” Microbes and Infection, vol. 10, no. 10-11, pp. 1201–1209, 2008. View at: Publisher Site | Google Scholar
  10. M. Dhiman, Y. A. Coronado, C. K. Vallejo et al., “Innate immune responses and antioxidant/oxidant imbalance are major determinants of human chagas disease,” PLoS Neglected Tropical Diseases, vol. 7, no. 8, Article ID e2364, 2013. View at: Publisher Site | Google Scholar
  11. M. Dhiman, J. G. Estrada-Franco, J. M. Pando et al., “Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with chagas' disease,” Clinical and Vaccine Immunology, vol. 16, no. 5, pp. 660–666, 2009. View at: Publisher Site | Google Scholar
  12. J.-J. Wen, P. C. Yachelini, A. Sembaj, R. E. Manzur, and N. J. Garg, “Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients,” Free Radical Biology and Medicine, vol. 41, no. 2, pp. 270–276, 2006. View at: Publisher Site | Google Scholar
  13. C. Grond-Ginsbach, M. Hummel, T. Wiest et al., “Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke,” Journal of Neurology, vol. 255, no. 5, pp. 723–731, 2008. View at: Publisher Site | Google Scholar
  14. S. S. Kassner, R. Kollmar, G. A. Bonaterra, W. Hildebrandt, S. Schwab, and R. Kinscherf, “The early immunological response to acute ischemic stroke: differential gene expression in subpopulations of mononuclear cells,” Neuroscience, vol. 160, no. 2, pp. 394–401, 2009. View at: Publisher Site | Google Scholar
  15. L. M. Smith and N. L. Kelleher, “Proteoform: a single term describing protein complexity,” Nature Methods, vol. 10, no. 3, pp. 186–187, 2013. View at: Publisher Site | Google Scholar
  16. Y. Guo, S. K. Sanganalmath, W. Wu et al., “Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injury,” Basic Research in Cardiology, vol. 107, no. 2, article 253, 2012. View at: Publisher Site | Google Scholar
  17. K. Tyagarajan, E. Pretzer, and J. E. Wiktorowicz, “Thiol-reactive dyes for fluorescence labeling of proteomic samples,” Electrophoresis, vol. 24, no. 14, pp. 2348–2358, 2003. View at: Publisher Site | Google Scholar
  18. E. Pretzer and J. E. Wiktorowicz, “Saturation fluorescence labeling of proteins for proteomic analyses,” Analytical Biochemistry, vol. 374, no. 2, pp. 250–262, 2008. View at: Publisher Site | Google Scholar
  19. C. W. Turck, A. M. Falick, J. A. Kowalak et al., “The association of biomolecular resource facilities proteomics research group 2006 study: relative protein quantitation,” Molecular & Cellular Proteomics, vol. 6, no. 8, pp. 1291–1298, 2007. View at: Publisher Site | Google Scholar
  20. J. E. Wiktorowicz, S. Stafford, H. Rea et al., “Quantification of cysteinyl S-nitrosylation by fluorescence in unbiased proteomic studies,” Biochemistry, vol. 50, no. 25, pp. 5601–5614, 2011. View at: Publisher Site | Google Scholar
  21. T. C. Savidge, P. Urvil, N. Oezguen et al., “Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins,” Nature Medicine, vol. 17, no. 9, pp. 1136–1141, 2011. View at: Publisher Site | Google Scholar
  22. M. Sheffield-Moore, J. E. Wiktorowicz, K. V. Soman et al., “Sildenafil increases muscle protein synthesis and reduces muscle fatigue,” Clinical and Translational Science, vol. 6, no. 6, pp. 463–468, 2013. View at: Publisher Site | Google Scholar
  23. F. G. Bouwman, B. De Roos, I. Rubio-Aliaga et al., “2D-electrophoresis and multiplex immunoassay proteomic analysis of different body fluids and cellular components reveal known and novel markers for extended fasting,” BMC Medical Genomics, vol. 4, article 24, 2011. View at: Publisher Site | Google Scholar
  24. T. Rabilloud, M. Chevallet, S. Luche, and C. Lelong, “Two-dimensional gel electrophoresis in proteomics: past, present and future,” Journal of Proteomics, vol. 73, no. 11, pp. 2064–2077, 2010. View at: Publisher Site | Google Scholar
  25. K. Imai, A. Koshiyama, and K. Nakata, “Towards clinical proteomics analysis,” Biomedical Chromatography, vol. 25, no. 1, pp. 59–64, 2011. View at: Publisher Site | Google Scholar
  26. A. Miseta and P. Csutora, “Relationship between the occurrence of cysteine in proteins and the complexity of organisms,” Molecular Biology and Evolution, vol. 17, no. 8, pp. 1232–1239, 2000. View at: Publisher Site | Google Scholar
  27. H. de Barjac, “New facts and trends in bacteriological control of mosquitoes,” Memorias do Instituto Oswaldo Cruz, vol. 84, pp. 101–105, 1989. View at: Google Scholar
  28. E. Weerapana, C. Wang, G. M. Simon et al., “Quantitative reactivity profiling predicts functional cysteines in proteomes,” Nature, vol. 468, no. 7325, pp. 790–795, 2010. View at: Publisher Site | Google Scholar
  29. M. Dhiman, E. S. Nakayasu, Y. H. Madaiah et al., “Enhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: implications in Chagas' disease,” American Journal of Pathology, vol. 173, no. 3, pp. 728–740, 2008. View at: Publisher Site | Google Scholar
  30. A. R. Brasier, J. Garcia, J. E. Wiktorowicz et al., “Discovery proteomics and nonparametric modeling pipeline in the development of a candidate biomarker panel for dengue hemorrhagic fever,” Clinical and Translational Science, vol. 5, no. 1, pp. 8–20, 2012. View at: Publisher Site | Google Scholar
  31. J. H. Friedman and C. B. Roosen, “An introduction to multivariate adaptive regression splines,” Statistical Methods in Medical Research, vol. 4, no. 3, pp. 197–217, 1995. View at: Publisher Site | Google Scholar
  32. M. Dhiman, M. P. Zago, S. Nunez et al., “Cardiac-oxidized antigens are targets of immune recognition by antibodies and potential molecular determinants in chagas disease pathogenesis,” PLoS ONE, vol. 7, article e28449, 2012. View at: Publisher Site | Google Scholar
  33. J.-J. Wen, M. P. Zago, S. Nuñez, S. Gupta, F. N. Burgos, and N. J. Garg, “Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease,” Molecular and Cellular Proteomics, vol. 11, no. 8, pp. 435–452, 2012. View at: Publisher Site | Google Scholar
  34. N. Dey, M. Sinha, S. Gupta et al., “Caspase-1/ASC inflammasome-mediated activation of IL-1beta-ROS-NF-kappaB pathway for control of Trypanosoma cruzi replication and survival is dispensable in NLRP3−/− macrophages,” PLoS ONE, vol. 9, Article ID e111539, 2014. View at: Google Scholar
  35. H.-L. Yu, H. M. Chertkow, H. Bergman, and H. M. Schipper, “Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma,” Proteomics, vol. 3, no. 11, pp. 2240–2248, 2003. View at: Publisher Site | Google Scholar
  36. P. C. Austin, “A comparison of regression trees, logistic regression, generalized additive models, and multivariate adaptive regression splines for predicting AMI mortality,” Statistics in Medicine, vol. 26, no. 15, pp. 2937–2957, 2007. View at: Publisher Site | Google Scholar | MathSciNet
  37. N. R. Cook, R. Y. L. Zee, and P. M. Ridker, “Tree and spline based association analysis of gene-gene interaction models for ischemic stroke,” Statistics in Medicine, vol. 23, no. 9, pp. 1439–1453, 2004. View at: Publisher Site | Google Scholar
  38. L. Boscá, S. González-Ramos, P. Prieto et al., “Metabolic signatures linked to macrophage polarization: from glucose metabolism to oxidative phosphorylation,” Biochemical Society Transactions, vol. 43, pp. 740–744, 2015. View at: Publisher Site | Google Scholar
  39. R. Carnicer, M. J. Crabtree, V. Sivakumaran, B. Casadei, and D. A. Kass, “Nitric oxide synthases in heart failure,” Antioxidants and Redox Signaling, vol. 18, no. 9, pp. 1078–1099, 2013. View at: Publisher Site | Google Scholar
  40. K. Takahashi, T. Osanai, T. Nakano, M. Wakui, and K. Okumura, “Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure,” Heart and Vessels, vol. 16, no. 6, pp. 249–256, 2002. View at: Publisher Site | Google Scholar
  41. E. Takimoto, “Cyclic GMP-dependent signaling in cardiac myocytes,” Circulation Journal, vol. 76, no. 8, pp. 1819–1825, 2012. View at: Publisher Site | Google Scholar
  42. Y. Wang, P. Zhang, Z. Xu et al., “S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation,” Free Radical Biology and Medicine, vol. 86, Article ID 12452, pp. 343–351, 2015. View at: Publisher Site | Google Scholar
  43. E. Mustonen, H. Ruskoaho, and J. Rysä, “Thrombospondins, potential drug targets for cardiovascular diseases,” Basic and Clinical Pharmacology and Toxicology, vol. 112, no. 1, pp. 4–12, 2013. View at: Publisher Site | Google Scholar
  44. N. G. Frangogiannis, G. Ren, O. Dewald et al., “Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts,” Circulation, vol. 111, no. 22, pp. 2935–2942, 2005. View at: Publisher Site | Google Scholar
  45. Y. Xia, M. Dobaczewski, C. Gonzalez-Quesada et al., “Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism,” Hypertension, vol. 58, no. 5, pp. 902–911, 2011. View at: Publisher Site | Google Scholar
  46. M. Swinnen, D. Vanhoutte, G. C. Van Almen et al., “Absence of thrombospondin-2 causes age-related dilated cardiomyopathy,” Circulation, vol. 120, no. 16, pp. 1585–1597, 2009. View at: Publisher Site | Google Scholar
  47. A.-P. Papageorgiou, M. Swinnen, D. Vanhoutte et al., “Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells,” Cardiovascular Research, vol. 94, no. 1, pp. 115–124, 2012. View at: Publisher Site | Google Scholar
  48. S. Belmadani, J. Bernal, C.-C. Wei et al., “A thrombospondin-1 antagonist of transforming growth factor-β activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II,” American Journal of Pathology, vol. 171, no. 3, pp. 777–789, 2007. View at: Publisher Site | Google Scholar
  49. I. Mikhailenko, D. Krylov, K. M. Argraves, D. D. Roberts, G. Liau, and D. K. Strickland, “Cellular internalization and degradation of thrombospondin-1 is mediated by the amino-terminal heparin binding domain (HBD). High affinity interaction of dimeric HBD with the low density lipoprotein receptor-related protein,” The Journal of Biological Chemistry, vol. 272, no. 10, pp. 6784–6791, 1997. View at: Publisher Site | Google Scholar
  50. N. M. Rogers, M. Sharifi-Sanjani, G. Csányi, P. J. Pagano, and J. S. Isenberg, “Thrombospondin-1 and CD47 regulation of cardiac, pulmonary and vascular responses in health and disease,” Matrix Biology, vol. 37, pp. 92–101, 2014. View at: Publisher Site | Google Scholar
  51. Z. Liu, S. Morgan, J. Ren et al., “Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm,” Circulation Research, vol. 117, no. 2, pp. 129–141, 2015. View at: Publisher Site | Google Scholar
  52. M. E. W. Janssen, E. Kim, H. Liu et al., “Three-dimensional structure of vinculin bound to actin filaments,” Molecular Cell, vol. 21, no. 2, pp. 271–281, 2006. View at: Publisher Site | Google Scholar
  53. A. Zemljic-Harpf, A. M. Manso, and R. S. Ross, “Vinculin and talin: focus on the myocardium,” Journal of Investigative Medicine, vol. 57, no. 8, pp. 849–855, 2009. View at: Publisher Site | Google Scholar
  54. W. Xu, H. Baribault, and E. D. Adamson, “Vinculin knockout results in heart and brain defects during embryonic development,” Development, vol. 125, no. 2, pp. 327–337, 1998. View at: Google Scholar
  55. H. A. Rockman, R. S. Ross, A. N. Harris et al., “Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 18, pp. 8277–8281, 1991. View at: Publisher Site | Google Scholar
  56. A. E. Zemljic-Harpf, J. C. Miller, S. A. Henderson et al., “Cardiac-myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy,” Molecular and Cellular Biology, vol. 27, no. 21, pp. 7522–7537, 2007. View at: Publisher Site | Google Scholar
  57. V. C. Vasile, W. D. Edwards, S. R. Ommen, and M. J. Ackerman, “Obstructive hypertrophic cardiomyopathy is associated with reduced expression of vinculin in the intercalated disc,” Biochemical and Biophysical Research Communications, vol. 349, no. 2, pp. 709–715, 2006. View at: Publisher Site | Google Scholar
  58. T. M. Olson, S. Illenberger, N. Y. Kishimoto, S. Huttelmaier, M. T. Keating, and B. M. Jockusch, “Metavinculin mutations alter actin interaction in dilated cardiomyopathy,” Circulation, vol. 105, no. 4, pp. 431–437, 2002. View at: Publisher Site | Google Scholar
  59. A. R. Wende, “Post-translational modifications of the cardiac proteome in diabetes and heart failure,” PROTEOMICS—Clinical Applications, vol. 10, no. 1, pp. 25–38, 2016. View at: Publisher Site | Google Scholar
  60. F. del Monte and G. Agnetti, “Protein post-translational modifications and misfolding: new concepts in heart failure,” PROTEOMICS—Clinical Applications, vol. 8, no. 7-8, pp. 534–542, 2014. View at: Publisher Site | Google Scholar

Copyright © 2016 Sue-jie Koo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

950 Views | 727 Downloads | 8 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder